Wegovy Gains Singapore Nod, First for Critical Liver Disease MASH with Fibrosis
Context mode is active. Hover over any highlighted term to see its definition. Click a nested term to go deeper.
Novo Nordisk has secured a landmark approval in Singapore for its blockbuster drug Wegovy, making it the first treatment cleared in the country for adults battling metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis. This approval from Singapore's Health Sciences Authority (HSA) on September 23, 2026, marks a significant step forward for patients facing this progressive and often 'silent' liver disease, offering a new therapeutic option beyond lifestyle changes. The decision is based on compelling data from the company's Phase 3 ESSENCE trial, which showed Wegovy effectiveness in resolving steatohepatitis without worsening liver scarring. This latest regulatory win follows Wegovy earlier accelerated approvals for MASH in the US by the FDA in August 2025 and in the UK by the MHRA in July 2026, solidifying Novo Nordisk position in a rapidly expanding therapeutic area. MASH, previously known as NASH, is a severe form of fatty liver disease that can lead to life-threatening complications like cirrhosis and liver cancer, and its prevalence is on the rise globally, closely linked to the growing rates of obesity and type 2 diabetes. While Madrigal Pharmaceuticals' Rezdiffra also received US approval for MASH earlier, Wegovy, a GLP-1 receptor agonist, offers a differentiated approach by targeting systemic metabolic dysfunction, which is a major driver of the disease. The Singapore approval is expected to pave the way for wider access and deeper market penetration in Asia for Novo Nordisk, further cementing Wegovy role beyond its initial indications for weight management and cardiovascular risk reduction. As the ESSENCE trial continues to evaluate long-term outcomes, the focus will now shift to patient access, pricing, and the rollout strategy in Singapore and potentially other regional markets. This development underscores the pharmaceutical industry's intensified efforts to address MASH, a disease poised to become a leading cause of liver transplants worldwide.